Our Programs

Our pipeline includes four clinical-stage drug candidates targeting different mechanisms critical to overcoming cancer progression and drug resistance:

• Pracinostat, an oral HDAC inhibitor;
• ME-401, an oral PI3K delta inhibitor;
• Voruciclib, an oral CDK inhibitor; and
• ME-344, a mitochondrial inhibitor targeting the OXPHOS complex.

Our portfolio is built around drug candidates with validated targets and is designed to develop medicines that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other medicines.

† Phase 2 study intended to support an accelerated approval marketing application with the FDA
‡ Study arm to be initiated under clinical collaboration with Beigene, Ltd.
§ Investigator-initiated study